Zydus Pivots To Multivariant COVID-19 Vaccine, Looks To Revlimid Opportunity
Board Approves Share Buyback
Zydus is pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response. It also looks to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa.
